Pages

Search This Website

Wednesday, 17 March 2021

US company Ridgeback claims:Covid's new drug will reduce viral load in 5 days



US company Ridgeback claims:Covid's new drug will reduce viral load in 5 days, prevent increasing number of corona in the body




Scientists in the United States developed the Corona tablet.

Scientists in the United States have developed a Corona tablet

Ridgeback Biotherapeutics, a US company that develops a new drug called Molnupiravir, released its research results on Saturday.

Also Read 
'ઘોસ્ટ બર્ડ' ચીસો સાંભળીને ડરી ગયેલી મહિલા, આ ડરામણી પક્ષી અને મહિલા વચ્ચેની વાતચીતનો વીડિયો વાયરલ થયો છે


Scientists in the United States have developed a Corona tablet. An initial study on this drug found that it reduces the viral load. Treatment lasting 5 days reduced the number of viruses in the patient. Ridgeback Biotherapeutics, an American company that develops a new drug called Molnupiravir, released the results of a pre-study so far on Saturday. If the drug is successful in the trial it will be the first oral antiviral drug against corona.


According to the company's co-founder Wayne Holman, the results of the research so far show that the new drug prevents the increasing number of corona in the body (replication). It proves that this drug can be effective in fighting corona. However, the results of the research so far do not prove 100 percent that it will completely reduce the impact of the disease. There is still much research to be done.

Also Read 
બેરોજગારીની આગ બુઝાવશે ફાયર સેફ્ટી ઓફિસર, FSO પ્રોજેક્ટ 2 લાખ રોજગારીનું સર્જન કરશે


This is how the drug works

against Corona so far. The drug targets its spike protein and prevents infection. But this new drug from the American drug company attacks the part of the corona that increases its number in the body.



Extensive research results to be

released by end of March According to the company, detailed research results will be available by the end of March to determine how effective the new drug Molnupiravir is in preventing corona patients from being hospitalized. How much it reduces the risk of death.

According to Carl Defenbeck, director of the National Institute of Infectious Diseases, the results of the research are interesting but not 100 percent accurate. The results need to be further proven in clinical trials.

No comments:

Follow Us